Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration

Ophthalmology

Volumn 120, Issue 1, 2013, Pages 115-121

  Abedi, Farshad ^a   Wickremasinghe, Sanjeewa ^a   Richardson, Andrea J ^a   Makalic, Enes ^a   Schmidt, Daniel F ^a   Sandhu, Sukhpal S ^a   Baird, Paul N ^a   Guymer, Robyn H ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN A;

AGED; ALLELE; ARTICLE; FOLLOW UP; GENE; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; VASCULOTROPIN A GENE; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; GENOTYPE; GENOTYPING TECHNIQUES; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; SEQUENCE TAGGED SITES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84872022283     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2012.10.006     Document Type: Article

References (22)

1. C.H. Meyer, F.G. Holz Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab Eye (Lond) 25 2011 661 672
2. P.J. Rosenfeld, D.M. Brown, J.S. Heier MARINA Study Group Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431
3. D.M. Brown, M. Michels, P.K. Kaiser ANCHOR Study Group Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study Ophthalmology 116 2009 57 65
4. CATT Research Group D.F. Martin, M.G. Maguire, G.S. Ying et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 2011 1897 1908
5. F.G. Holz, W. Amoaku, J. Donate SUSTAIN Study Group Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study Ophthalmology 118 2011 663 671
6. U. Schmidt-Erfurth, B. Eldem, R. Guymer EXCITE Study Group Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE Study Ophthalmology 118 2011 831 839
7. M. McKibbin, M. Ali, S. Bansal CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration Br J Ophthalmol 96 2012 208 212
8. S.J. Teper, A. Nowinska, J. Pilat et al. Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration Mol Vis [serial online] 16 2010 2598 2604 http://www.molvis.org/molvis/v16/a278/ Accessed August 8, 2012
9. C. Nischler, H. Oberkofler, C. Ortner Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration [report online] Acta Ophthalmol 89 2011 e344 e349
10. S.S. Wickremasinghe, J. Xie, J. Lim Variants in the APOE gene are associated with improved outcome after anti-VEGF treatment for neovascular AMD Invest Ophthalmol Vis Sci 52 2011 4072 4079
11. D.W. Leung, G. Cachianes, W.J. Kuang Vascular endothelial growth factor is a secreted angiogenic mitogen Science 246 1989 1306 1309
12. C.N. Nagineni, V.K. Kommineni, A. William Regulation of VEGF expression in human retinal cells by cytokines: implications for the role of inflammation in age-related macular degeneration J Cell Physiol 227 2012 116 126
13. N. Ferrara Vascular endothelial growth factor: basic science and clinical progress Endocr Rev 25 2004 581 611
14. L.E. Lantry Ranibizumab, a mAb against VEGF-A for the potential treatment of age-related macular degeneration and other ocular complications Curr Opin Mol Ther 9 2007 592 602
15. B. Kloeckener-Gruissem, D. Barthelmes, S. Labs Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD Invest Ophthalmol Vis Sci 52 2011 4694 4702
16. I. Nakata, K. Yamashiro, H. Nakanishi VEGF gene polymorphism and response to intravitreal bevacizumab and triple therapy in age-related macular degeneration Jpn J Ophthalmol 55 2011 435 443
17. P.K. Kaiser, D.M. Brown, K. Zhang Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results Am J Ophthalmol 144 2007 850 857
18. D.S. Boyer, A.N. Antoszyk, C.C. Awh MARINA Study Group Subgroup analysis of the MARINA Study of ranibizumab in neovascular age-related macular degeneration Ophthalmology 114 2007 246 252
19. H. Gerding, V. Loukopoulos, J. Riese Results of flexible ranibizumab treatment in age-related macular degeneration and search for parameters with impact on outcome Graefes Arch Clin Exp Ophthalmol 249 2011 653 662
20. H. Ding, Q. Liu, M. Hua Polymorphisms of hypoxia-related genes in subjects susceptible to acute mountain sickness Respiration 81 2011 236 241
21. L. Dumont, C. Mardirosoff, M.R. Tramer Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review BMJ 321 2000 267 272
22. M.C. Tissot van Patot, G. Leadbetter, L.E. Keyes Greater free plasma VEGF and lower soluble VEGF receptor-1 in acute mountain sickness J Appl Physiol 98 2005 1626 1629